key: cord-0834016-x7c0j9vx
authors: Sokal, Aurélien; Barba-Spaeth, Giovanna; Fernández, Ignacio; Broketa, Matteo; Azzaoui, Imane; La Selle, Andrea de; Vandenberghe, Alexis; Fourati, Slim; Roeser, Anais; Meola, Annalisa; Bouvier-Alias, Magali; Crickx, Etienne; Languille, Laetitia; Michel, Marc; Godeau, Bertrand; Gallien, Sébastien; Melica, Giovanna; Nguyen, Yann; Zarrouk, Virginie; Canoui-Poitrine, Florence; Noizat-Pirenne, France; Megret, Jérôme; Pawlotsky, Jean-Michel; Fillatreau, Simon; Bruhns, Pierre; Rey, Felix A.; Weill, Jean-Claude; Reynaud, Claude-Agnès; Chappert, Pascal; Mahévas, Matthieu
title: Memory B cells control SARS-CoV-2 variants upon mRNA vaccination of naive and COVID-19 recovered individuals
date: 2021-06-17
journal: bioRxiv
DOI: 10.1101/2021.06.17.448459
sha: aa04e17391978da2b4e9b9e0ed2a9d5b5b39445c
doc_id: 834016
cord_uid: x7c0j9vx

How a previous SARS-CoV-2 infection may amplify and model the memory B cell (MBC) response elicited by mRNA vaccines was addressed by a comparative longitudinal study of two cohorts, naive individuals and disease-recovered patients, up to 2 months after vaccination. The quality of the memory response was assessed by analysis of the VDJ repertoire, affinity and neutralization against variants of concerns (VOC), using unbiased cultures of 2452 MBCs. Upon boost, the MBC pool of recovered patients selectively expanded, further matured and harbored potent neutralizers against VOC. Maturation of the MBC response in naive individuals was much less pronounced. Nevertheless, and as opposed to their weaker neutralizing serum response, half of their RBD-specific MBCs displayed high affinity towards multiple VOC and one-third retained neutralizing potency against B.1.351. Thus, repeated vaccine challenges could reduce these differences by recall of affinity-matured MBCs and allow naive vaccinees to cope efficiently with VOC.

To whom correspondence should be addressed: pascal.chappert@inserm.fr or matthieu.mahevas@aphp.fr

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in more than 165 million infections and at least 3.5 million deaths. Vaccination represents the main hope to control the pandemic. COVID-19 vaccines containing nucleoside-modified mRNA encoding the original Wuhan-Hu-1 SARS-CoV-2 spike glycoprotein (S) developed by Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) are now being deployed worldwide. They were shown to be safe, highly effective to prevent infection and to control disease severity (Baden et al., 2021; Dagan et al., 2021; Polack et al., 2020) .

The emergence of SARS-CoV-2 variants bearing mutations in key B cell epitopes, however, has raised concerns that viral evolution will erode natural immunity or the protection offered by vaccination. One early mutation in the spike protein (D614G), which shifts the equilibrium between the open and closed protein conformation without modifying antibody neutralization, has become globally dominant (Plante et al., 2021; Weissman et al., 2021; Yurkovetskiy et al., 2020) . Since then, novel variants of concern (VOC) or of interest K417T, E484K, N501Y in the P.1 (gamma) variant and L452R, E484Q, or L452R, T478K in the B1.617.1 (kappa) and B1.617.2 (delta) variants, respectively (Cherian et al., 2021; Davies et al., 2021; Greaney et al., 2021a; Tegally et al., 2021) .

Higher infectiousness of the B.1.1.7 variant does not impair neutralizing antibody response (Davies et al., 2021; Garcia-Beltran et al., 2021; Planas et al., 2021; Supasa et al., 2021) . By contrast, E484K and K417T/N mutations in the B.1351 and P.1 strains markedly reduced the neutralization potency in COVID-19 recovered or naive vaccinated individuals (Cele et al., 2021; Edara et al., 2021; Greaney et al., 2021a; Hoffmann et al., 2021; Planas et al., 2021; Wang et al., 2021a; Xie et al., 2021) . Even though infection with VOC/VOI remain possible after successful vaccination (Hacisuleyman et al., 2021) , the effectiveness of the BNT162b2 vaccine against B.1.351 in preventing severe disease was recently demonstrated during the vaccination campaign in Qatar (Abu-Raddad et al., 2021) .

In addition to the serum IgG response, the generation of memory B cell (MBC) against the SARS-CoV-2 virus represents another layer of immune protection (Dugan et al., 2021; Gaebler et al., 2021; Rodda et al., 2021; Sakharkar et al., 2021; Sokal et al., 2021) . MBCs not only persist after infection but continuously evolve and mature by progressive acquisition of somatic mutations in their variable region genes to improve affinity through an ongoing germinal center response, potentially driven by antigenic persistence Rodda et al., 2021; Sokal et al., 2021) . MBCs further drive the recall response after antigenic rechallenge by differentiating into new antibody-secreting cells (ASC) displaying the diverse array of high-affinity-antibodies contained in the MBC repertoire.

The remarkable convergence of the anti-RBD response across COVID-19 recovered and naive vaccinated individuals shaped by recurrent germline gene families may favor viral mutational escape as one single mutation in the RBD can confer a selective advantage by reducing binding and neutralizing activity of antibodies (Garcia-Beltran et al., 2021; Greaney et al., 2021a) . This can be theoretically counter-balanced by the diversity of the MBC repertoire, which contains a broad variety of clones with different specificities. Upon vaccination, COVID-19 recovered patients showed a striking expansion of RBD-specific

MBCs (Goel et al., 2021; Wang et al., 2021b) and elicited a strong serum antibody response including cross-neutralizing antibodies against VOC (Ebinger et al., 2021; Konstantinidis et al., 2021; Manisty et al., 2021; Saadat et al., 2021; Samanovic et al., 2021; Stamatatos et al., 2021; Wang et al., 2021b) . Much less is known about the long-term stability, dynamics and functionality of the MBC repertoire after repeated antigenic stimulation. How the MBC pool will contract or expand its diversity after a new challenge is of major importance in the context of vaccination schemes with repeated homologous or heterologous booster doses and coexistence of multiple variants of concerns. Here, we longitudinally characterized the dynamics, clonal evolution, affinity and neutralization capacity of anti-SARS-CoV-2 memory B cell response after mRNA vaccination in naive and SARS-CoV-2 recovered individuals from the analysis of over two thousand naturally expressed antibodies from single-cell cultured RBD-specific MBCs.

Our study explores the intrinsic diversity of the MBC repertoire selected against RBD protein upon infection and/or vaccination and its capacity to cope with multiple variants of SARS-CoV-2. We demonstrate that mRNA vaccination selects high-affinity neutralizing clones without compromising the overall MBC pool.

individuals.

The B cell immune response elicited by vaccination was compared between two cohorts, one of patients previously infected with SARS-CoV-2 six months to one year ago and one of virus-naive individuals having received, respectively, one or two doses of the Pfizer-BioNTech mRNA vaccine (BNT162b2). We previously characterized the longitudinal evolution and maturation, up to 6 months after infection, of SARS-CoV-2-responding B cells in a cohort of mild ambulatory (M-CoV) and severe forms of COVID-19 requiring oxygen (S-CoV) . These patients have all been infected during the first pandemic wave in France. Thirty-four patients from this cohort, further referred to as SARS-CoV-2 recovered, were sampled at 12 months (see Table S1 ). Table S1 ) and was referred to as vaccine "boost". For SARS-CoV-2 naïve patient the second vaccine dose, also referred to as "boost", was received in median 28 days after initial priming. Post-boost blood samples were collected from all vaccinated participants in median 8 days (range 5-22 days) and 2 months after the injection ( Figure 1A and see Table S1 ). Eight SARS-CoV-2 naive donors were additionally sampled after the first dose of vaccine, referred to as "prime".

We first measured the pre-and post-boost evolution of WT RBD IgG serum titers in SARS-CoV-2 recovered patients. Anti-RBD IgG levels remained remarkably stable between 6 (M6) and 12 months (M12) post-infection, with only a mild decrease seen in S-CoV patients ( Figure 1B ). In line with previous reports, a single dose of mRNA vaccine elicited a strong recall response in all patients, with anti-RBD IgG titers increasing on average by 24-fold in S-CoV and 53-fold in M-CoV patients as compared with pre-boost titers ( Figure 1C) .

In SARS-CoV-2 naive individuals, the mRNA vaccine boost also induced a robust anti-RBD IgG response (average of 25-fold-increase) although titers remained inferior to SARS-CoV-2-recovered patients at all time points (mean 10,870 vs. 75,511 UA/mL in S-CoV and 55,024 in M-CoV, P-value 0.005 and <0.0001, respectively). Despite contraction of the response in all groups, anti-RBD IgG were at least 10-fold higher than pre-boost/prime levels at 2 months post boost ( Figure 1C ).

To further assess the neutralizing activity against circulating variants of concern (VOC) in sera from SARS-CoV-2 recovered and naive individuals, we performed neutralization assays, using a focus reduction neutralization test with authentic SARS-CoV-2 viruses carrying the dominant Spike protein D614G amino acid change in the S1 domain of the S protein, and on the B.1.351 VOC harboring three mutations in the RBD (N501Y, which increases the affinity for the ACE2 receptor, E484K and K417N, which are implicated in escape from neutralizing antibodies (Harvey et al., 2021) ), along with several mutations in other Spike domains. Twelve months after infection, all sera from recovered patients demonstrated neutralization potential against the D614G SARS-CoV-2 strain, which was more pronounced in S-CoV than in M-CoV ( Figure 1D -E and Figure S1 ). As expected, this potential was similarly reduced in both groups against the B.1.351 VOC strain. As previously reported (Goel et al., 2021; Reynolds et al., 2021; Stamatatos et al., 2021; Wang et al., 2021b) , a boost mRNA vaccine strongly enhanced the overall neutralizing potency of SARS- To track the dynamics of the overall SARS-CoV-2-specific B cell response after mRNA vaccine boost, we used successive staining with His-tagged RBD from the Wuhan-Hu-1 strain and two fluorescently labeled anti-His antibodies to stain SARS-CoV-2 RBDspecific B cells (Figure 2A and Figure S2A ). We focused on RBD recognition because it represents a large fraction of the virus neutralization potency, but we also analyzed S-specific cells in all samples, using a similar staining strategy. The percentage of RBD-specific and Sspecific CD27 + IgD -B cells appeared remarkably stable between 6 and 12 months in SARS-CoV-2 recovered patients, irrespectively of initial disease severity, thus confirming the generation of germinal-center-derived long-lived memory B cell after natural infection To further analyze the impact of mRNA vaccine on the memory B cell compartment in SARS-CoV-2 recovered patients, we performed multi-parametric FACS analysis using the same flow panel which we previously used to describe the initial response against SARS-CoV-2 in these patients and which includes 7 surface markers (CD19, CD21, CD27, CD38, CD71, CD11c, IgD) and His-tagged RBD staining to characterize the main B cell subsets. Unsupervised analysis of CD19 + IgDswitched B cell populations showed that RBD-specific cells mostly resided in the CD21 + CD27 + IgD -CD38 int/-CD71 int/resting memory B cell compartment before vaccination ( Figure 2D -F). These cells rapidly switched to a CD27 + CD38 int/+ CD71 + activated B cell phenotype (ABC cluster), in the first 7 days after the boost, together with the emergence of a population of RBD + CD38 high CD27 high ASCs.

These activated subsets progressively contracted and matured as resting memory B cells at the latest time point in our study. Atypical memory B cells (DN2; IgD -CD27 +/-CD11c + ) and ASC precursors (DN1; IgD -CD27 -) RBD-specific clusters were also observed, with a small DN2 fraction persisting up to two months post boost, notably in S-CoV patients ( Figure 2F ).

The low numbers of RBD-specific B cells in naive patients precluded a robust unsupervised analysis, and we therefore characterized the phenotype of RBD-specific memory B cells from the whole cohort using manual gating, based on the CD19 and CD71 expression profiles, to delineate activated B cells (CD19 high CD71 + ) and resting MBCs To address how mRNA vaccine boost affects the MBC repertoire, we then performed single cell sorting and culture of RBD-specific memory B cells before, 7 days and 2 months after the boost in SARS-CoV-2 recovered patients, and 2 months after the boost in naive individuals ( Figure 3A ). We obtained a total of 2452 VH sequences from 4 S-CoV, 4-M-CoV and 3 naive individuals (Table S1 and S2). Clonally expanded RBD-specific MBC were found before vaccination in all SARS-CoV-2 recovered patients, representing 13-34% of total VH sequences for each donor ( Figure 3B and Figure S3A ). Vaccine-activated MBC showed no evidence of further clonal dominance and conserved their overall diversity, despite the major increase in MBC numbers. The fraction of the repertoire belonging to these clones varies from 19-39%, and remains comparable during contraction, with clones persisting over the pre/post vaccination period observed in all SARS-CoV-2 recovered patients. This overall clonal stability was reflected by similar Shannon entropy values at all studied time points ( Figure S3B ). Similar clonal expansion was observed in naive individuals ( Figure 3C ), which also harbored high level of convergent RBD-specific clones with SARS-CoV-2 recovered patients based on VH sequences ( Figure 3D ).

We previously reported, up to 6 months after infection in this cohort of SARS-CoV-2 recovered patients, a progressive accumulation of somatic mutations in RBD-specific clones . The mutation level of RBD-specific VH sequences remained stable between 6 and 12 months. In contrast, VH mutation numbers were significantly increased shortly after the boost and this level was maintained in the MBC pool 2 months after ( Figure   3E ). This evolution in mutation profile could further be confirmed at the individual level for 2 patients with complete follow-up from 6 months post symptom onset to 2 months after boost ( Figure S3C-D) . This rapid increase in overall mutational load suggests that a fraction of matured, pre-existing MBCs was selectively mobilized upon vaccine response and persisted over time.

RBD-specific MBCs from naive individuals obtained 2 months after the boost harbored low mutation numbers in their VH genes, consistent with the recruitment of naive B cells in the early phase of the vaccine response. It should moreover be noted that MBCs from naive individuals harbor even lower mutational load than MBCs from SARS-CoV-2 recovered patients at a similar 3 months time point after natural infection ( Figure 3E ). This suggests that natural infection might drive a faster maturation process of the MBC response.

RBD-specific antibody secreting cells (ASC) from SARS-CoV-2 recovered patients sorted 7 days after the boost showed clonal relationships with MBCs and highly mutated VH sequences ( Figure 3F -H and Figure S2A ). In contrast, RBD-specific ASC from naive individuals displayed near germline VH sequences corresponding to the recruitment of naive B cells in the extra-follicular response. Overall, these results show that the activation of the previously matured pool of MBCs by the mRNA vaccine does not bias the clonal diversity of their repertoire in previously infected individuals, while selectively amplifying MBCs with a higher mutation load.

To determine the potency of the MBC compartment mobilized or elicited by mRNA vaccine against the main natural RBD variants, we first performed ELISA assays on 1583

supernatants Overall, the natural distribution of mutations in the various VOC RBD ( Figure 4I ) allowed us to predict the identity of key binding amino acid residues within the RBD for 142 out of 414 tested memory B cell-derived monoclonal antibodies ( Figure 4G -H and Figure S4C -D). In agreement with recent structural studies (Yuan et al., 2021) , clones recognizing the K417 residue were highly enriched for IGHV3-53 and 3-66 genes, whereas clones recognizing the E484K/Q residue were mostly enriched for the IGHV1-2 and 1-69 genes ( Figure S4E ). These results also allowed us to ascribe RBD binding residues of B cells within individual memory repertoires of naive and recovered patients, confirming the major targeting of the E484 residue within the vaccine activated pool ( Figure 4J ), but also highlighting significant interdonor variability in the overall recognition profile of the SARS-CoV-2 RBD by their memory B cell repertoire.

Finally, to evaluate whether RBD-specific clones mobilized after vaccination, Figure 5E ), maintenance of neutralization activity against the VOC was strongly dictated by original affinity against the WT RBD.

Whereas clones with weak affinity against WT RBD were mostly impaired, 40% of clones with high initial affinity against WT RBD remained potent neutralizers against the VOC (white dots in the grey sector, Figure 5E ). This included monoclonals directed against both the E484 and K417 residues of SARS-CoV-2 RBD ( Figure S5B ). This highlights the key role of affinity maturation in shaping the humoral response and anticipating viral escape.

Overall, these results demonstrate that the MBC pool selected against the WT RBD after mRNA vaccination contains, among its diverse and affinity matured repertoire, a substantial fraction of potent neutralizers against VOC.

Memory B cells display a diverse repertoire allowing for an adaptive response upon re-exposure to the pathogen, especially in the case of variants (Purtha et al., 2011; Weisel et al., 2016) . However, repeated antigenic stimulation, either with vaccinations or viral challenge may be deleterious, reducing the diversity of the overall response in which drifted epitopes are less well targeted (Andrews et al., 2015; Mesin et al., 2020) . Thus, understanding how mRNA vaccination impacts the memory B cell pool shaped by a previous exposure to SARS-CoV-2 and to determine its capacity to neutralize variants is critical. More generally, to decipher how memory B cells from naive vaccinees differ and evolve in comparison with SARS-CoV-2 recovered patients is also of major importance in the pandemic context.

We report here a longitudinal study of SARS-CoV-2 recovered patients, followed over Our study demonstrates a remarkable stability of the overall RBD-specific memory B cell population up to 12 months after infection with a stable mutation profile, extending observations on memory persistence in COVID-19 (Wang et al., 2021b) . Dynamics of RBDspecific cells after mRNA vaccination in SARS-CoV-2 recovered patients reflect the plasticity of the MBC pool, which promptly and widely activates, proliferates and generates

ASCs, and then contracts as resting memory B cells (Goel et al., 2021; Reynolds et al., 2021; Wang et al., 2021b) . This mobilized population, with a higher mutational load than before vaccinal boost, contains highly-mutated affinity-matured clones that settle, expand and persist for up to 2 months after the boost at a higher level than before. Despite this, longitudinal VDJ sequencing revealed a limited impact on the diversity of this previously matured repertoire.

Thus, the expansion of the MBC pool does not seem to impair archives of the B cell specificities that have been selected during the amplification. In contrast, and mirroring early stages of the extrafollicular response after infection (Woodruff et al., 2020) , RBD-specific B cells expressing near germline recurrent VH genes with potent affinity are recruited after mRNA vaccination in naive individuals. MBC from naive individuals also acquired somatic mutations with time but harbored, 2 months after the boost, fewer mutations than SARS-CoV-2 recovered patients 3 months after COVID-19. Thus, whereas the MBC pool progressively matures in naive vaccinees, its maturation and amplification were less pronounced, resulting in less RBD-specific MBCs compared to SARS-CoV-2 recovered patients at 12 months after infection (respectively 7.8 and 3 times less than S-CoV and M-CoV) and 2 months after the boost (respectively 18.2 and 6 times less than S-CoV and M-CoV).

As previously reported, most sera of SARS-CoV-2 recovered patients efficiently neutralized the B1.351 variant after mRNA vaccine, which contrasted with the significant lower neutralization potency of the sera of naïve vaccinated individuals (Goel et al., 2021; Reynolds et al., 2021; Stamatatos et al., 2021; Wang et al., 2021b) . This likely reflects the quality and maturation of the B cell pool mobilized by the vaccine, i.e. an extrafollicular response in naive vaccinees and a mature MBC response in recovered patients.

A fraction of recurrent and convergent VH genes of memory B cells failed to recognize the B.1351 variant RBD in both cohorts but a large proportion of clones retained high affinity against this variant. This is consistent with a recent report showing that B cell clones expressing potent antibodies are selectively retained in the repertoire over time (Wang et al., 2021b) . This phenomenon occurs independently of the mutational load, high-affinity clones against variants being "randomly" present in the memory repertoire of SARS-CoV-2 recovered or naive individuals. So, despite the fact that amplitude and quality of the MBC response after mRNA vaccine appears to be lower in naive than in previously infected individuals, high-affinity clones with neutralizing potency against VOC settle in their repertoire, suggesting that their MBC pool could compensate for the time-dependent decay of the initial antibody response.

Correlation of neutralization and affinity shows a complex profile for antibodies expressed by memory B cells. Immune escape can affect high-affinity clones against WT RBD, but at the same time, a proportion of clones with high affinity for WT RBD maintain neutralizing potency against B1.351, contrasting with clones with low or weak affinity that constantly failed to neutralize variants. It indicates that high affinity provides some flexibility for antibodies to cope with mutations affecting their binding target and to conserve their neutralization potency. Consistent with structural analysis (Yuan et al., 2021) , determination of targeted epitopes using binding of different RBD of VOC shows that E484 preferentially affected the binding affinity of the IGHV1-2/1-69 genes, and K417N and N501Y the one of IGHV3-53/3-66 and IGHV1-2. It underlines, that if particular antibody lineages are affected by RBD mutations, others may retain neutralizing properties Greaney et al., 2021b Greaney et al., , 2021c Muecksch et al., 2021; Scheid et al., 2021; Wang et al., 2021b) .

Altogether, these data describe an immune response maturing with time in SARS-CoV-2 convalescent patients, and resulting in a massive, high-affinity response after vaccination, which, even imprinted by the Wuhan-type RBD, displays an improved recognition of the RBD variants as well. In this immune evolution scheme, the response of naive vaccinees nevertheless lags behind the maturation process that took place during infection. Our observations suggest that repeated challenges, even against the original spike protein, will compensate for these differences by recall of affinity-matured memory B cells and allow vaccinated people to cope efficiently with most variants actually described.

We Figure S1 and Table S1 . (***P<0.0001, *** P<0.001, **P < 0.01, *P < 0.05). See also Figure S2 and Table S2 . Ordinary one-way ANOVA with multiple comparisons (Benjamini, Krieger and Yekutieli FDR correction) (G) and a two-tailed Mann-Whitney test (E) were performed (****P<0.0001). See also Figure S3 and Table S2 . variants inside each group (black lines) and between groups for each tested variants (colored lines)) was performed (Benjamini, Krieger and Yekutieli FDR correction). (****P<0.0001, **P < 0.01, *P < 0.05). See also Figure S4 and Table S2 . Figure S5 and Table S2 . 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Matthieu Mahévas (matthieu.mahevas@aphp.fr).

No unique materials were generated for this study.

In total, 34 patients with recovered COVID-19 from the original MEMO-COV-2 cohort were Table S1 ). First injection was realized in mean 309 days (± SD 44.6 days) after the infection. Naive patients received two doses at a mean 27.7 days (± SD 1.8 days) interval.

Prior to vaccination, samples were collected from SARS-CoV-2 recovered patients 12 months post symptoms onset (mean ±SD 329.1 ± 15: 8.8 days after disease onset for S-CoV, and 342.0 ± 8.6 days after disease onset for M-CoV). Samples at 12 months post disease onset were defined as "pre-boost". For patients not sampled before vaccination (n=9/34), sample at 6 months was considered as "pre-boost". For naive patients, the "prime" time-point was defined as the sampling between the two doses and was drawn at a mean 20.2 ± 5.9 days after the first injection.

Samples were additionally collected shortly after the boost (mean ±SD: 10 ± 5.3 days for S-CoV; 23 ± 6.1 days for M-CoV and 9 ± 4.0 days for naive), and 2 months after the boost (mean ±SD: 64.7 ± 15.3 days for S-CoV ; 63.2 ± 11.9 days for M-CoV and 63.3 ± 9.0 days for naive). Clinical and biological characteristics of these patients are summarized in Table   S1 . Patients were recruited at the Henri Mondor University Hospital (AP-HP), between March and April 2021. MEMO-COV-2 study (NCT04402892) was approved by the ethical committee Ile-de-France VI (Number: 40-20 HPS), and was performed in accordance with the French law. Written informed consent was obtained from all participants.

Quant II assay (ARCHITECT®, Abbott Laboratories). The latter assay is an automated chemiluminescence microparticle immunoassay (CMIA) that quantifies anti-RBD IgG, with 50 AU/mL as a positive cut-off and a maximal threshold of quantification of 40,000 AU/mL.

All assays were performed by trained laboratory technicians according to the manufacturer standard procedures.

The ectodomain from the SARS-CoV-2 Spike (residues 1-1208) was designed as a stabilized construct with six proline mutations (F817P, A892P, A899P, A942P, K986P, V987P), a GSAS substitution at the furin cleavage site (residues 682-685) and a C-terminal Foldon trimerization motif (Hsieh, 2020) , followed by Hisx8, Strep and Avi tags. This construct was cloned using its endogenous signal peptide in pcDNA3.1(+). 

Single cell culture was performed as previously described (Crickx et al., 2019) 

Clones whose culture had proven successful (IgG concentration ≥ 1 µg/mL at day 21-25)

were selected and extracted using the NucleoSpin96 RNA extraction kit (Macherey-Nagel) according to the manufacturer's instruction. A reverse transcription step was then performed using the SuperScript IV enzyme (ThermoFisher) in a 14 μl final volume (42°C 10 min, 25°C

10 min, 50°C 60 min, 94°C 5 min) with 4 µl of RNA and random hexamers (Thermofisher scientific). A PCR was further performed based on the protocol established by Tiller et al (Tiller et al., 2008) . Briefly, 3.5 μl of cDNA was used as template and amplified in a total volume of 40 μl with a mix of forward L-VH primers ( For specific patients and time points (see Table S1 ), some IgH sequences were obtained directly from single-cell sorting in 4 µL lysis buffer containing PBS (Gibco), DTT (ThermoFisher) and RNAsin (Promega). Reverse transcription and a first PCR was performed as described above (50 cycles) before a second 50-cycles PCR using 5'AgeI VH primer mix and CHG-D1 3' primer, before sequencing.

Processed FASTA sequences from cultured single-cell VH sequencing were annotated using 

Biolayer interferometry assays were performed using the Octet HTX instrument (ForteBio).

Anti-Human Fc Capture (AHC) biosensors (18-5060) were immersed in supernatants from single-cell memory B cell culture (or control monoclonal antibody) at 25°C for 1800 seconds.

Biosensors were equilibrated for 10 minutes in buffer prior to measurement. Association was performed for 600 s in PBS-BT with WT or variant RBD at 100nM followed by dissociation for 600s in PBS-BT. Biosensor regeneration was performed by alternating 30s cycles of regeneration buffer (glycine HCl, 10 mM, pH 2.0) and 30s of PBS-BT for 3 cycles. Traces were reference sensor subtracted and curve fitting was performed using a local 1:1 binding model in the HT Data analysis software 11.1 (ForteBio). Sensors with response values below 0.1nm were excluded or considered non-binding. For binding clones, only those with full R²>0.8 were retained for further analysis.

The reference D614G strain (hCoV-19/France/GE1973/2020) and the B. All tested mAbs

Butt, A.A., and National Study Group

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Immune history profoundly affects broadly protective B cell responses to influenza

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra

Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Infection-and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Evolution of antibody immunity to SARS-CoV-2

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination

Comprehensive mapping of mutations in the SARS-CoV-2 receptorbinding domain that affect recognition by polyclonal human plasma antibodies

Comprehensive mapping of mutations in the SARS-CoV-2 receptorbinding domain that affect recognition by polyclonal human plasma antibodies

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

SARS-CoV-2 variants, spike mutations and immune escape

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Structure-based design of prefusionstabilized SARS-CoV-2 spikes

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Levels of produced antibodies after vaccination with mRNA vaccine; effect of previous infection with SARS-CoV-2

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Restricted Clonality and Limited Germinal Center Reentry Characterize Memory B Cell Reactivation by Boosting

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Spike mutation D614G alters SARS-CoV-2 fitness

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Prolonged evolution of the human B cell response to SARS-CoV-2 infection

Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals

B cell genomics behind crossneutralization of SARS-CoV-2 variants and SARS-CoV

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Detection of a SARS-CoV-2 variant of concern in South Africa

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

A Temporal Switch in the Germinal Center Determines Differential Output of Memory B and Plasma Cells

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant

SARS-CoV2 Recovered: Severe Covid-19 (n= 17) Mild Covid-19